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Better prediction of drug disposition prior to the clinical trial is critical for the efﬁcient development of
new drugs. The purpose of this study is to develop a novel multiple assessment methodology of hepa-
tocellular drug disposition from drug uptake to efﬂux including biliary and basolateral excretion, in a
single packaged procedure. We started a sandwich culture using rat primary hepatocytes. After ﬁve days
culture, the hepatocytes were incubated with a dosing solution including CDF or Rhodamine 123. Three
distinct sequences were then performed in parallel: disrupting and maintaining the tight junctions
comprising a bile canalicular network at 37 C, and maintaining the network at 4 C. Supernatant
fractions were collected from each sequence, and followed by the cell lysate collection. The disposition
rates of basolateral efﬂux by diffusion, by transporter-mediation, biliary excretion, and residual cellular
fraction of CDF and Rhodamine 123 were 38.2% and 11.0%, 26.6% and 12.1%, 18.6% and 4.9%, and, 16.7% and
72.0%, respectively. CDF was likely to excrete extracellularly whereas Rhodamine 123 tended to remain
intracellularly. CDF showed a relatively higher biliary excretion rate than Rhodamine 123. This novel
protocol may contribute to improve the predictability of pharmacokinetics eventually in human, and
streamline new drug development.
Chemical compounds: 5(6)-Carboxy-20 ,70-dichloroﬂuoroscein (PubChem CID: 132525); Rhodamine 123
(PubChem CID: 65217).
Copyright © 2015 The Authors. Published by Elsevier Ltd on behalf of The Japanese Society for the Study of
Xenobiotics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Clinically relevant prediction of drug disposition during the
early stages of drug development is critical for the efﬁcient devel-
opment of new drugs. In recent years, two of the primary factors
behind the current low clinical success rate of drug candidates
(~11%) [13] are lack of efﬁcacy (56%) and safety issues (28%) [2],
which have been ﬁrst detected in the late clinical study stages of the
drug development process. In order to reduce the attrition rate,
there is a growing need for an in vitro methodology that can clarify
the entire pharmacokinetics of a drug eventually applied for better
prediction in humans.
Primary hepatocytes have been widely used as effective cell
sources for DMPK-related or toxicological study. The sandwich
culture system was proposed in the late 1980s as a way to mimicm (R. Takahashi), katsuhiro.
y Elsevier Ltd on behalf of The Japa
es/by-nc-nd/4.0/).the hepatocytes of an in vivo environment [3,4]. The sandwich-
cultured hepatocytes exhibited the structural polarity with bile
canalicular network and the localization of proper hepatobiliary
transporters on the network, maintaining liver-speciﬁc functions
for several days [9,18]. This culture method has been utilized for
investigating the hepatic disposition of drugs. In vitro biliary
clearance determined in sandwich-cultured hepatocytes correlates
well with in vivo biliary clearance [7], and biliary clearance calcu-
lation based on the intracellular concentration of a drug has the
potential to reﬂect more the in vivo process than that based on
incubation medium [11]. In another report, basolateral and biliary
clearance was revealed to be an alternative elimination route in
sandwich-cultured hepatocytes by combining biliary excretion and
basolateral efﬂux experiment individually [14].
The objective of this study is to consider these previous reports
as a basis and develop an in vitromultiple assessmentmethodology
using hepatocytes to determine the entire picture of drug dispo-
sitions including uptake, biliary excretion, and basolateral efﬂux
disposition in a single packaged procedure. The evaluation of these
endpoints at the same time in a single procedure has not beennese Society for the Study of Xenobiotics. This is an open access article under the CC
R. Takahashi et al. / Drug Metabolism and Pharmacokinetics 31 (2016) 167e171168reported. Furthermore, diffusion and transporter-mediated efﬂux
can be distinguished by controlling the speciﬁc experimental
conditions.
2. Materials and methods
2.1. Chemicals
5(6)-Carboxy-2,70-dichloroﬂuoroscein (CDF) and Aprotinin
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). Rhodamine 123 (Rh 123), Insulin, and Epidermal Growth
Factor (EGF) were purchased from SigmaeAldrich (St. Louis, MO).
Penicillinestreptomycin solution and Dexamethasone was pur-
chased from Nakalai Tesque, Inc. (Kyoto, Japan). Matrigel was pur-
chased from BD Bioscience (San Jose, CA). All other chemicals and
reagents were of analytical grade and readily available from com-
mercial sources.
2.2. Hepatocyte culture
Hepatocytes were isolated from six- to eight-week-old speciﬁc
viral-pathogen-free male SD rats weighing about 150e250 g
(Charles River Japan Inc., Japan) by modiﬁed two-step in situ
collagenase perfusion and puriﬁed by Percoll gradient separation
[8,15]. Hepatocytes with over 90% viability were used for the
following culture.
The hepatocytes were resuspended in William's E medium
(SigmaeAldrich) containing 10% fetal bovine serum, supplemented
with 8.6 nM insulin, 255 nM dexamethasone, 50 ng/ml EGF, and
5 KIU/ml aprotinin, and seeded at a density of 1 105 cells/cm2 into
a type I collagen-coated 24-well culture dish (AGC Techno Glass Co.,
Ltd., Chiba, Japan). The seeded hepatocytes were incubated in a
humidiﬁed chamber with 5% CO2 at 37 C. After 24 h of post-
seeding, the culture medium was replaced with serum-free Wil-
liam's E medium containing Matrigel with the same supplements
described above. Subsequently, the culture medium without
Matrigel was changed daily. Hepatocyteswere cultured for a total of
four days.
2.3. Fluorescent and phasecontrast microscopy
Sandwich-cultured hepatocytes were rinsed with standard (Std)
Hanks' balanced salt solution (HBSS) containing Ca2þ and Mg2þ on
day 5 and then incubated with a dosing solution including 10 mM
CDF or 10 mM Rh 123 in the 5% CO2 incubator. After 30-min incu-
bation, HBSS was removed and the hepatocytes were washed with
Std HBSS. Fluorescent and phasecontrast micrographs of the he-
patocytes were acquired with a Zeiss Axiovert 200 inverted optical
microscope (Carl Zeiss Microscopy GmbH, Germany).
2.4. Disposition study
Sandwich-cultured hepatocytes were rinsed and preincubated
in the 37 C, 5% CO2 incubator with Std HBSS containing Ca2þ and
Mg2þ (Std HBSS) on day 5, which the MRP2 expression still main-
tained in a high rate [16]. Hepatocytes were then incubated with a
dosing solution including 10 mM CDF or 10 mM Rh 123 (Fig. 1) in the
CO2 incubator for 30 min. After incubation, the dosing solution was
aspirated from the cells and the uptake process was stopped by
washing the cells with ice-cold Std HBSS. Subsequently, three
different sequences were performed in parallel: one, disrupting the
tight junctions comprising a bile canalicular network at 37 C by
Ca2þ, Mg2þ-free HBSS with EGTA (seq. 1), two, maintaining the
network at 37 C by Std HBSS (seq. 2), and three, maintaining the
network at 4 C by Std HBSS (seq. 3). The supernatant fractionswere collected from each sequence after 30 min incubation. Finally,
cells were lysed with 1% Triton X-100 in H2O and cell lysate was
collected. The samples were analyzed for relative luminescence
unit (RLU) of CDF and Rh 123 by microplate reader.
2.5. Data analysis
The disposition rates of each fraction were calculated using the
obtained ﬂuorescent data. B2 corresponds to the amount of total
basolateral efﬂux, B3 corresponds to that of basolateral efﬂux by
diffusion, B2  B3 corresponds to that of basolateral efﬂux medi-
ated by transporters, B1  B2 corresponds to that of biliary efﬂux,
and C1 corresponds to that of intracellular residue. In this analysis,
B1þ C1 which represents putative intracellular drug amount in the
beginning of the efﬂux fractionation process was counted as 100%.
The disposition rate of total basolateral efﬂux (BEfx-Total), baso-
lateral efﬂux by diffusion (BEfx-Dif), basolateral efﬂux by trans-
porter (BEfx-TP), biliary efﬂux (BCEfx), and intracellular residue
(Cell) were calculated by Eqs. (1)e(5), respectively.
BEfx-Total ¼ B2/(B1 þ C1) (1)
BEfx-Dif ¼ B3/(B1 þ C1) (2)
BEfx-TP ¼ (B2  B3)/(B1 þ C1) (3)
BCEfx ¼ (B1  B2)/(B1 þ C1) (4)
Cell ¼ C1/(B1 þ C1) (5)
3. Results and discussion
CDF and Rh 123 were independently exposed to sandwich-
cultured rat hepatocytes to examine the localization of these two
compounds (Fig. 1), which are not subject to hepatic metabolism
and primarily excreted in an unchanged form [1,21]. CDF has been
used as a model ﬂuorescent compound to evaluate the excretion
into bile canaliculi byMultidrug Resistant-associated Protein (MRP)
2 [10,21]. Rh 123, also a ﬂuorescent substance, has been used to
determine mitochondrial membrane potential [20] and is currently
used to label mitochondria in living cells [5]. CDF was accumulated
in the bile canalicular network of sandwich-cultured hepatocytes
for 30-min incubation (Fig. 1). In contrast, Rh 123 was localized in
the cytoplasm (Fig. 1). These results indicate the characteristics of
the two tested compounds.
Multiple drug disposition assay was performed on day 5 ac-
cording to the protocol described in Materials and methods and
Fig. 2. We incubated with CDF or Rh 123 for 30 min at the uptake
process. Due to the existing reports, uptake time is generally
applied 10e20 min [6,12,19]. Whereas their uptake condition
requires two different SCRH buffers with Ca2þ/Mg2þ and without
Ca2þ/Mg2þ, our protocol is performed only with Ca2þ/Mg2þ,
which is favorable to maintain hepato-cellularly stable condition
with intact intercellular adhesion. Accordingly, our uptake con-
dition enables prolonged absorption of the drugs in SCRH. We
applied 30 min for efﬂux experiment because of the results based
on the preliminary experiment (data not shown). The time-
course of supernatant ﬂuorescence of efﬂux fractions saturated
at about 30 min. We concluded 30 min was suitable for efﬂux
study.
In order to calculate the disposition rate of biliary excretion, the
supernatant fraction of B2 was subtracted from the B1 fraction
(Fig. 2). The calculation of transporter-mediated basolateral efﬂux
was performed by subtracting B3, a supernatant of the 4 C
Fig. 1. Chemical structure, property and micrographic images of 5(6)-carboxy-2,70-dichloroﬂuoroscein (CDF) and Rhodamine 123. Fluorescent and phasecontrast micrographs of
sandwich-cultured rat hepatocytes. Sandwich-cultured hepatocytes were incubated with 10 mM CDF (A, B) or with 10 mM Rh 123 (C, D) for 30 min. Dosing solution was rinsed with
Std HBSS, ﬂuorescent micrograph (A, C) and phasecontrast micrograph (B, D) were taken on day 5.
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basolateral efﬂux (BEfx-Total), basolateral efﬂux by diffusion (BEfx-
Dif), by transporter-mediation (BEfx-TP), biliary excretion (BCEfx),
and residual cellular fraction (Cell) of CDF and Rh 123 were
64.75 ± 7.39% and 47.98 ± 1.61%, 38.15 ± 4.01% and 10.94 ± 0.51%,
26.60± 7.54% and 12.11± 1.26%,18.58± 4.60% and 4.92± 0.82%, and
16.67 ± 3.34% and 72.02 ± 2.82% according to Eqs. (1)e(5),
respectively (Table 1). CDF and Rh 123 are extensively known to be
substrates of multiple transporters such as MRP2 [16], MRP3 and P-
gp [17], which expressed in sandwich-cultured rat hepatocytes at
day 5. CDF was likely to excrete extracellularly whereas Rh 123
tended to remain intracellularly. Additionally, CDF showed a rela-
tively higher biliary excretion rate than Rh 123. These results show
the disposition rate of CDF is different from that of Rh 123, which
reﬂects the properties and the localization depending on the
compounds illustrated in Fig. 1. We introduced sequence 3 to
distinguish the transporter-mediated and passive-diffusion efﬂux
process operated under 4 C. In order to seek the reliability andprecision of the methodology, the transporter inhibition study us-
ing several statins and inhibitors is under evaluation.
The amount of total uptake can be calculated by the sum of the
fractionation processes S, B and C in the developed protocol. How-
ever,wedeﬁned the fractionationprocess S (Fig. 2) as the process for
transition to an apparent steady state of mass transfer, to ensure the
following efﬂux more stable, because our purpose in this experi-
ment is to evaluate the disposition rate based on efﬂux fractions.
Therefore, fraction S was not included as a part of the denominator
that corresponds to the total amount of accumulated compounds,
and instead, the sumof the following recovered fractionsBandCwas
deﬁned as the total amount, which represents the intracellular total
drug amount in the beginning of the efﬂux study. From this view-
point, the disposition rates were calculated using Eqs. (1)e(5).
In conclusion, we have developed a multiple assessment
methodology for hepatocellular drug disposition. Our methodology
can evaluate overall disposition including in vitro uptake, biliary
excretion and basolateral efﬂux, in a single packaged procedure.
Fig. 2. Scheme depicting multiple assay protocol for hepatocellular drug disposition. Three distinct sequences were performed in fractionation process B in parallel: one, disrupting
tight junctions comprising a bile canalicular network at 37 C (seq. 1), two, maintaining the network at 37 C (seq. 2), and three, maintaining the network at 4 C (seq. 3). Basolateral
efﬂux by diffusion (a) is described by B3, basolateral efﬂux by transporter (b) is calculated by B2  B3, biliary excretion (c) is calculated by B1  B, and intracellular fraction (d) is
indicated by C1.
Table 1
Disposition rates of CDF and Rhodamine 123. The disposition rate of basolateral efﬂux by diffusion (BEfx-Dif), basolateral efﬂux by transporter (BEfx-TP), biliary efﬂux (BCEfx),
and intracellular residue (Cell) were calculated by Eqs. (1)e(5), respectively. Data represents mean ± SD of four individual assays.
Compound BEfx-Total BEfx-Dif BEfx-TP BCEfx Cell
%
CDF 64.75 ± 7.39 38.15 ± 4.01 26.60 ± 7.54 18.58 ± 4.60 16.67 ± 3.34
Rhodamine 123 47.98 ± 1.61 10.95 ± 0.52 12.11 ± 1.26 4.92 ± 0.82 72.02 ± 2.82
Equation (1) (2) (3) (4) (5)
R. Takahashi et al. / Drug Metabolism and Pharmacokinetics 31 (2016) 167e171170Moreover, the protocol also has a potential to distinguish diffusion
and transporter-mediated efﬂux. In addition, all the compounds are
dosed under an identical cellular condition which the bile cana-
licular network of sandwich-cultured hepatocytes is maintained.
The fundamental advantage of this protocol would be expected to
allow the processes from the drug uptake to the fractionation
process S thoroughly treated under a stable condition for
sandwich-cultured hepatocytes, which contributes to precise ana-
lyses. Our novel protocol with the advantages above has a potential
to contribute to streamline the development process of new drugs.
Acknowledgments
We are grateful to Ms. Akiko Hisada and Mr. Hiroshi Sonoda for
their helpful comments and suggestions. We also thank Ms. Kimie
Mase and Ms. Yumi Mizunuma for technical assistance.
This study was funded by the in-house research budget of
Hitachi High-Technologies Corp. and Hitachi, Ltd. The authors have
no conﬂicts of interest.
References
[1] Ando H, Nishio Y, Ito K, Nakao A, Wang L, Zao YL, et al. Effect of endotoxin on
P-glycoprotein-mediated biliary and renal excretion of Rhodamine-123 in
rats. Antimicrob Agents Chemother 2001;45:3462e7.
[2] Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates
2011e2012. Nat Rev Drug Discov 2013;12:569.[3] Caron JM. Induction of albumin gene transcription in hepatocytes by extra-
cellular matrix proteins. Mol Cell Biol 1990;10:1239e43.
[4] Dunn JC, Yarmush ML, Koebe HG, Tompkins RG. Hepatocyte function and
extracellular matrix geometry: long-term culture in a sandwich conﬁguration.
FASEB J 1989;3:174e7.
[5] Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of trans-
membrane potential in isolated rat-liver mitochondria: spectral and metabolic
properties. Biochim Biophys Acta 1986;850:436e48.
[6] Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I. Effect of plasma protein
binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated
by sandwich-cultured rat hepatocytes. Drug Metab Dispos 2008;36:1275e82.
[7] Ghibellini G, Vasist LS, Leslie EM, Heizer WD, Kowalsky RJ, Calvo BF, et al.
In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin
Pharmacol Ther 2007;81:406e13.
[8] Kreamer BL, Staecker JL, Sawada N, Sattler GL, Hsia MT, Pitot HC. Use of a low-
speed, iso-density percoll centrifugation method to increase the viability of
isolated rat hepatocyte preparations. In Vitro Cell Dev Biol 1986;22:201e11.
[9] LeCluyse EL, Audus KL, Hochman JH. Formation of extensive canalicular net-
works by rat hepatocytes cultured in collagen-sandwich conﬁguration. Am J
Physiol 1994;266:C1764e74.
[10] Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, et al. Biliary
excretion in primary rat hepatocytes cultured in a collagen-sandwich
conﬁguration. Am J Physiol 1999;277:G12e21.
[11] Nakakariya M, Ono M, Amano N, Moriwaki T, Maeda K, Sugiyama Y. In vivo
biliary clearance should be predicted by intrinsic biliary clearance in
sandwich-cultured hepatocytes. Drug Metab Dispos 2012;40:602e9.
[12] Nakanishi T, Shibue Y, Fukuyama Y, Yoshida K, Fukuda H, Shirasaka Y, et al.
Quantitative time-lapse imaging-based analysis of drug-drug interaction
mediated by hepatobiliary transporter, multidrug resistance-associated pro-
tein 2, in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2011;39:
984e91.
[13] Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR,
et al. How to improve R&D productivity: the pharmaceutical industry's grand
challenge. Nat Rev Drug Discov 2010;9:203e14.
R. Takahashi et al. / Drug Metabolism and Pharmacokinetics 31 (2016) 167e171 171[14] Pfeifer ND, Yang K, Brouwer KL. Hepatic basolateral efﬂux contributes
signiﬁcantly to rosuvastatin disposition I: characterization of basolateral
versus biliary clearance using a novel protocol in sandwich-cultured hepa-
tocytes. J Pharmacol Exp Ther 2013;347:727e36.
[15] Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:
29e83.
[16] Takahashi R, Sonoda H, Tabata Y, Hisada A. Formation of hepatocyte spheroids
with structural polarity and functional bile canaliculi using nanopillar sheets.
Tissue Eng Part A 2010;16:1983e95.
[17] Takahashi R, Hisada A, Sonoda H. Comprehensive expression analysis of pri-
mary hepatocytes under four different culture conditions. Gene Expression
Omnibus accession number GSE38950. 2012.[18] Talamini MA, Kappus B, Hubbard A. Repolarization of hepatocytes in culture.
Hepatology 1997;25:167e72.
[19] Tian X, Zamek-Gliszczynski MJ, Zhang P, Brouwer KL. Modulation of multidrug
resistance-associated protein 2 (Mrp2) and Mrp3 expression and function
with small interfering RNA in sandwich-cultured rat hepatocytes. Mol Phar-
macol 2004;66:1004e10.
[20] Wu EY, Smith MT, Bellomo G, Di Monte D. Relationships between the mito-
chondrial transmembrane potential, ATP concentration, and cytotoxicity in
isolated rat hepatocytes. Arch Biochem Biophys 1990;282:358e62.
[21] Zamek-GliszczynskiMJ, XiongH, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL.
Pharmacokinetics of 5 (and 6)-carboxy-20 ,70-dichloroﬂuorescein and its diac-
etate promoiety in the liver. J Pharmacol Exp Ther 2003;304:801e9.
